Want to see FR:ALMDT full AI Analyst Report?

Median Technologies (ALMDT) Price & Analysis

20 Followers

ALMDT Stock Chart & Stats

€4.45

€0.10(2.35%)

At close: Jul 31 4:00 PM EDT

€4.45

€0.10(2.35%)

Day’s Range― - ―

52-Week Range€2.63 - €7.27

Previous CloseN/A

Volume515.80K

Average Volume (3M)149.77K

Market Cap

€192.86M

Enterprise Value€180.92

Total Cash (Recent Filing)€18.41M

Total Debt (Recent Filing)€21.76M

Price to Earnings (P/E)―

Beta0.75

Next Earnings

Oct 29, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.15

Shares Outstanding49,048,060

10 Day Avg. Volume172,099

30 Day Avg. Volume149,766

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)-4.95

Price to Sales (P/S)7.45

P/FCF Ratio-9.58

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.44

Revenue Forecast (FY)€26.25M

Bulls Say, Bears Say

Bulls Say

Oncology Imaging SpecializationA focused position in oncology imaging aligns the company with a clinically important and structurally growing use of AI. Its software addresses tumor characterization, clinical research and drug development, creating multiple durable applications for specialized expertise.

Revenue GrowthThe acceleration from 3.2% revenue growth in 2024 to 21.5% in 2025 indicates improving commercial traction. If sustained, expanding revenue can increase operating scale, strengthen customer reach and provide a larger base from which to improve future profitability.

Diversified Commercial ModelThe business model serves both biopharmaceutical development and healthcare delivery, reducing reliance on a single end market. Combining project-based imaging services with software licensing, subscriptions and support creates several paths for durable revenue expansion.

Bears Say

Deep And Persistent LossesSevere and recurring losses show that revenue growth has not yet translated into a viable earnings model. This weak profitability can constrain reinvestment, limit strategic flexibility and leave results highly sensitive to execution, pricing and cost improvement.

Ongoing Cash BurnPersistent operating cash outflows mean the company is not currently funding its activities through internally generated cash. Continued burn can require external financing or balance-sheet capacity, increasing funding dependence and reducing resilience during operational setbacks.

Negative Equity And Weak Capital BaseNegative equity materially reduces financial flexibility and leaves less capital available to absorb losses or support expansion. Combined with meaningful, volatile debt, the weak capital base increases financing risk and may constrain future capital-allocation choices.

Median Technologies News

Median Technologies Wins €8.4 Million Global Phase III Brain Cancer Imaging Contract

Median Technologies ( ($FR:ALMDT) ) has provided an announcement. Median Technologies has secured one of the largest contracts...

9d ago

Median Technologies sets H1 2026 earnings date and intensifies investor outreach

The latest announcement is out from Median Technologies ( ($FR:ALMDT) ). Median Technologies has outlined its upcoming financial...

14d ago

Median Technologies Updates Capital Structure and Outstanding Warrants

Median Technologies ( ($FR:ALMDT) ) just unveiled an update. Median Technologies disclosed updated capital and voting rights data,...

16d ago

Median Technologies launches strategic review to unlock value in AI oncology businesses

Median Technologies ( ($FR:ALMDT) ) has provided an update. Median Technologies’ board has launched a Strategic Review Committee...

22d ago

Median Technologies Updates Share Capital and Warrants in Regulatory Filing

Median Technologies ( ($FR:ALMDT) ) has provided an update. Median Technologies has disclosed its latest capital structure and...

1M ago

Median Technologies strikes global Canon partnership to scale AI lung cancer screening

Median Technologies ( ($FR:ALMDT) ) has issued an announcement. Median Technologies has signed a global strategic commercial partnership...

2M ago

Median Technologies strengthens finances as eyonis lung cancer AI wins U.S. and EU approval

Median Technologies ( ($FR:ALMDT) ) has shared an update. Median Technologies, a specialist in AI-based medical imaging software...

2M ago

Stifel Nicolaus Recommends ‘Buy’ for Median Technologies Amid Strategic Financial Moves and Growth Potential

In a report released today, from Stifel Nicolaus reiterated a Buy rating on Median Technologies, with a price...

11M ago

ALMDT FAQ

What was Median Technologies’s price range in the past 12 months?

Median Technologies lowest stock price was €2.63 and its highest was €7.27 in the past 12 months.

What is Median Technologies’s market cap?

Median Technologies’s market cap is €192.86M.

When is Median Technologies’s upcoming earnings report date?

Median Technologies’s upcoming earnings report date is Oct 29, 2026 which is in 35 days.

How were Median Technologies’s earnings last quarter?

Median Technologies released its earnings results on Apr 23, 2026. The company reported -€0.677 earnings per share for the quarter.

Is Median Technologies overvalued?

According to Wall Street analysts Median Technologies’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Median Technologies pay dividends?

Median Technologies does not currently pay dividends.

What is Median Technologies’s EPS estimate?

Median Technologies’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Median Technologies have?

Median Technologies has 49,048,060 shares outstanding.

What happened to Median Technologies’s price movement after its last earnings report?

Median Technologies reported an EPS of -€0.677 in its last earnings report. Following the earnings report the stock price went up 1.957%.

Which hedge fund is a major shareholder of Median Technologies?

Currently, no hedge funds are holding shares in FR:ALMDT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Median Technologies

Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.